Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial

<p></p><p><b>Article full text</b></p><p><br></p><p>The full text of this article can be found here<b>. </b><u>https://link.springer.com/article/10.1007/s13300-018-0437-x</u></p><p><u><br></u></p><p><b>Provide enhanced content for this article</b></p><p><br></p><p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p><p><br></p><p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include, but are not limited to:</p><p><br></p><p>• Slide decks</p><p>• Videos and animations</p><p>• Audio abstracts</p><p> </p><p>• Audio slides</p><p></p

MOESM2 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Additional file 2. Questions and choices in Oral Hypoglycemic Agent-Questionnaire (OHA-Q) ver.2. The data on this file consist of the questions and choices in the Oral Hypoglycemic Agent-Questionnaire (OHA-Q) ver.2

MOESM3 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Additional file 3. Adverse events. The data on this file consist of all adverse events

MOESM1 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Additional file 1. List of the 29 medical institutions participating in the study. The data on this file include the names of the 29 participating medical institutions in this multi-center study

The changes in atherogenic lipid profiles (box plots).

<p>A, C: The percent changes in sd-LDL-C and RLP-C, respectively. B, D: sd-LDL-C and RLP-C values before and after the 12 weeks of treatment, respectively. The ‘before treatment’ values are shown as white bars and the ‘after treatment’ values are shown as black bars. n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.</p

Changes in LDL cholesterol (box plots).

<p><b>A. Percentage reduction of LDL-C after 12 weeks of treatment:</b> The solid bar represents the percent change in DST and the dotted bar represents the percent change in EST. B. <b>LDL-C values before and after 12 weeks of treatment:</b> The white bars represent basal values before treatment and the black bars represent values after treatment. The dotted textile indicates EAT therapy and the solid bar indicates DST therapy. n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.</p

Achievement rates in each treatment group.

<p>The bars representing the DST group are white and the bars representing the EAT group are black.</p

Baseline Characteristics of treatment groups.

<p>Baseline Characteristics of treatment groups.</p

Demographic profiles of treatment groups.

<p>Demographic profiles of treatment groups.</p

Flow of Patients in the RESEARCH Study.

<p>One hundred and nine patients were randomized. Fifty-six patients were assigned to the double intensified dose statin therapy (DST) group and 53 patients were assigned to the ezetimibe-add-on therapy (EAT) group. The analysis was performed on 51 patients in the EAT group and 56 patients in the DST group. T2DM: type 2 diabetes mellitus.</p